Editas Medicine Inc EDIT.OQ EDIT.O is expected to show a fall in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2025
The Cambridge Massachusetts-based company is expected to report a 81.7% decrease in revenue to $5.595 million from $30.6 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 83.5% above its last closing price of $2.18
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.30 | -0.30 | -0.28 | Beat | 5.5 |
Jun. 30 2025 | -0.37 | -0.38 | -0.63 | Missed | -67.1 |
Mar. 31 2025 | -0.61 | -0.59 | -0.92 | Missed | -56.2 |
Dec. 31 2024 | -0.19 | -0.36 | -0.55 | Missed | -54.2 |
Sep. 30 2024 | -0.72 | -0.75 | -0.75 | Met | -0.4 |
Jun. 30 2024 | -0.73 | -0.70 | -0.82 | Missed | -16.6 |
Mar. 31 2024 | -0.66 | -0.66 | -0.76 | Missed | -14.3 |
Dec. 31 2023 | -0.60 | -0.54 | -0.23 | Beat | 57.6 |
This summary was machine generated February 27 at 13:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments